Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation (Q36299062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Dietmar Tamandl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Christine Brostjan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

L Alidzanovic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

D Schauer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

T Maier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

C Nemeth

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

B Perisanidis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

B Gruenberger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

T Gruenberger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

31 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

961-966

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

9 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

30 September 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Clinical pharmacokinetics of therapeutic monoclonal antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Metastatic colorectal cancer: from improved survival to potential cure

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

VEGF-A: a critical regulator of blood vessel growth

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Modes of resistance to anti-angiogenic therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Presurgical chemotherapy in patients being considered for liver resection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464762

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

29 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Effect of molecular therapeutics on liver regeneration in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.342

Vascular endothelial growth factor and liver regeneration

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

12 December 2020

Neoadjuvant therapy with bevacizumab

1 reference

12 December 2020

Platelets Take Up the Monoclonal Antibody Bevacizumab

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FBJC.2012.342

7 January 2021

inferred from DOI database lookup

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases

1 reference

12 December 2020

Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.342

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

22850548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22850548%20AND%20SRC:MED&resulttype=core&format=json